Agra

Researchers are evaluating the safety and efficacy of centhaquine citrate LYFAQUIN173, a new drug for treating hypovolemic shock, a serious condition caused by severe blood or fluid loss. This phase IV, prospective, multi-center, open-label study builds on previous findings that centhaquine can improve blood pressure, reduce blood lactate levels, increase cardiac output, and reduce death rates by acting on specific adrenergic receptors to improve blood flow. Participants with hypovolemic shock aged 18 years or older and a systolic blood pressure of 90 mmHg or lower at hospital admission will receive centhaquine in addition to standard shock care. Centhaquine is given intravenously at a dose of 0.01 mgkg body weight over one hour in saline. A second dose may be given if blood pressure remains low, with a maximum of three doses in 24 hours, and treatment can continue for up to two days after enrollment. During hospitalization, participants will be closely monitored and followed until discharge or seven days after enrollment. Researchers will measure safety by tracking adverse events and serious adverse events up to seven days. They will also assess blood pressure, blood lactate, base deficit, time in intensive care, ventilator use, urine output, mortality rates, and organ function scores. Statistical analyses will compare patient outcomes to evaluate centhaquines effects.

Researchers are evaluating the Balanced Progressive Intensity Training BPIT 5-Line Principle, a 5-week supervised exercise program designed for healthy adults aged 18 to 65 years. The study focuses on how this training method influences functional movement efficiency, joint mobility, postural control, strength adaptation, and heart rate variability while tracking safety and individual responses to exercise intensity. Participants will engage in 3 to 5 supervised BPIT sessions per week, progressing through five levels of intensity based on anatomical landmarks and ground reaction forces. These levels include Ground-Based Low, Knee-Level Low-Moderate, Standing Moderate, Head-Level Moderate-High, and Plyometric High-Impact training. The entire program lasts five weeks, applying a structured increase in exercise challenge. Throughout the study, participants will undergo assessments at baseline and after five weeks, including functional movement screening, balance tests, strength measures, joint range of motion, and pain evaluation. Weekly monitoring will track resting heart rate variability and any training-related discomfort or minor injuries. The study aims to measure improvements in movement efficiency and neuromuscular adaptation while ensuring participant safety during the training period.